A 3-WEEK HEPATITIS-B VACCINATION SCHEDULE PROVIDES RAPID AND PERSISTENT PROTECTIVE IMMUNITY - A MULTICENTER, RANDOMIZED TRIAL COMPARING ACCELERATED AND CLASSIC VACCINATION SCHEDULES

被引:38
作者
MARCHOU, B
EXCLER, JL
BOURDERIOUX, C
SALAUN, J
PICOT, N
YVONNET, B
CERISIER, JE
SALOMON, H
AUVERGNAT, JC
机构
[1] HOP BRETONNEAU,SERV MALAD INFECT & TROP,PARIS,FRANCE
[2] FAC PHARM TOURS,INST VIROL,TOURS,FRANCE
[3] FAC PHARM TOURS,MICROBIOL LAB,TOURS,FRANCE
[4] CASERNE LOURCINES,PARIS,FRANCE
[5] PASTEUR MERIEUX SERUMS & VACCINS,MARNES COQUETTE,FRANCE
关键词
D O I
10.1093/infdis/172.1.258
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hepatitis B (HB) vaccinations given once weekly for 3 weeks can provide early seroprotection. This study compared immune responses induced by the accelerated (A; days 0, 10, 21) and classic (C; days 0, 28, 56) HB vaccination schedules. Two hundred seventy healthy subjects (95 men, 175 women) with a mean age of 23.8 years received 3 doses of GenHevac B, a recombinant vaccine produced in mammalian cells. The subjects were randomly assigned to schedules A or C. A booster dose was given 1 year later. One month after the third dose, 70% (schedule A) and 92% (schedule C) of the subjects were seroprotected and 100% (A) and 99% (C) of the subjects were seroprotected, and 1 month after the booster, almost all subjects were seroprotected. A 3-week HB vaccination schedule with GenHevac B can confer early protective immunity lasting up to 1 year.
引用
收藏
页码:258 / 260
页数:3
相关论文
共 15 条
[11]   ACCELERATED SCHEDULE OF HEPATITIS-B VACCINATION IN PATIENTS WITH HEMOPHILIA [J].
SANTAGOSTINO, E ;
MANNUCCI, PM ;
GRINGERI, A ;
RUMI, MG ;
RAFANELLI, D ;
ROCINO, A ;
SCHIAVONI, M ;
CHISTOLINI, A ;
DIBONA, E ;
MULEO, G .
JOURNAL OF MEDICAL VIROLOGY, 1993, 41 (02) :95-98
[12]   HEPATITIS-A AND HEPATITIS-B - RISKS COMPARED WITH OTHER VACCINE PREVENTABLE DISEASES AND IMMUNIZATION RECOMMENDATIONS [J].
STEFFEN, R .
VACCINE, 1993, 11 (05) :518-520
[13]   HEPATITIS-B VACCINE - DEMONSTRATION OF EFFICACY IN A CONTROLLED CLINICAL-TRIAL IN A HIGH-RISK POPULATION IN THE UNITED-STATES [J].
SZMUNESS, W ;
STEVENS, CE ;
HARLEY, EJ ;
ZANG, EA ;
OLESZKO, WR ;
WILLIAM, DC ;
SADOVSKY, R ;
MORRISON, JM ;
KELLNER, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1980, 303 (15) :833-841
[14]   RANDOMIZED DOSE RANGE STUDY OF A RECOMBINANT HEPATITIS-B VACCINE PRODUCED IN MAMMALIAN-CELLS AND CONTAINING THE S SEQUENCE AND PRES2 SEQUENCE [J].
TRON, F ;
DEGOS, F ;
BRECHOT, C ;
COUROUCE, AM ;
GOUDEAU, A ;
MARIE, FN ;
ADAMOWICZ, P ;
SALIOU, P ;
LAPLANCHE, A ;
BENHAMOU, JP ;
GIRARD, M .
JOURNAL OF INFECTIOUS DISEASES, 1989, 160 (02) :199-204
[15]   HEPATITIS-B VACCINATION WITH SHORT DOSE INTERVALS - A POSSIBLE ALTERNATIVE FOR POST-EXPOSURE PROPHYLAXIS [J].
WAHL, M ;
HERMODSSON, S ;
IWARSON, S .
INFECTION, 1988, 16 (04) :229-232